1. Managing IBD

2. Treatment of IBD

3. Management of IBD Sprint or Marathon?

4. Challenges and Unmet Needs

5. The Sprint

6. When Sprinting Matters

7. After the Sprint What Happens Next?

8. The Marathon

9. Long-Term Remission Why Is It Important?

10. Colectomy Rates in Patients With UC Are Decreasing Swiss IBD Cohort Study

11. Long-Term Remission Why Is It Important (cont)?

12. Steroids for the Treatment of CD Benefit for the Patient

13. Steroids for the Treatment of UC Symptomatic Control

14. Thiopurines Prevent the Need for Surgery in CD

15. Mucosal Healing as a Treatment Goal

16. Step Up, Top Down Early Aggressive Therapy Causes Mucosal Healing in CD

17. Achievement of Mucosal Healing With Immunomodulators and Biological Therapy

18. Benefits of Biological Agents for CD

19. Over Half of Patients Have a Primary or Secondary Loss of Response to Anti-TNF Therapies

20. Lasting Clinical Remission With Vedolizumab 5-Year Cumulative Exposure Data

21. Sustained Clinical Remission Rates With Ustekinumab (2-Year Data)

22. Immunogenicity of Newer Therapies

23. Best Practice for Managing the Sprint vs Marathon

24. Treatment Options Choosing a Biological Therapy for the Marathon

25. Evidence Beyond Clinical Trials on the Use of Vedolizumab and Ustekinumab

26. VICTORY Consortium Vedolizumab vs Anti-TNF Therapy (Propensity Score-Matched Analysis)

27. Key Considerations When Selecting a Therapy for an Individual Patient

28. Treatment Persistency

29. Targeting the Right Drug to the Individual Patient at the Right Time

30. Monitoring Patients Beyond Clinical Symptoms

31. Effective Infection Management May Improve Treatment Persistency

32. Concluding Remarks

33. Abbreviations